BioRestorative Therapies, Inc. (NASDAQ:BRTX) Short Interest Down 43.4% in March

BioRestorative Therapies, Inc. (NASDAQ:BRTX) was the recipient of a significant drop in short interest in March. As of March 15th, there was short interest totalling 405,200 shares, a drop of 43.4% from the February 28th total of 715,900 shares. Approximately 8.1% of the shares of the company are short sold. Based on an average daily volume of 371,800 shares, the short-interest ratio is currently 1.1 days.

Institutional Trading of BioRestorative Therapies

A hedge fund recently bought a new stake in BioRestorative Therapies stock. Citadel Advisors LLC bought a new stake in shares of BioRestorative Therapies, Inc. (NASDAQ:BRTX) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 21,481 shares of the company’s stock, valued at approximately $31,000. Citadel Advisors LLC owned approximately 0.31% of BioRestorative Therapies as of its most recent SEC filing. 69.38% of the stock is currently owned by institutional investors.

BioRestorative Therapies Trading Down 1.1 %

Shares of NASDAQ BRTX traded down $0.02 during midday trading on Friday, hitting $1.81. The company’s stock had a trading volume of 21,475 shares, compared to its average volume of 666,632. The firm has a market capitalization of $12.53 million, a price-to-earnings ratio of -1.18 and a beta of 64.37. The stock has a fifty day moving average price of $1.97 and a 200 day moving average price of $1.72. BioRestorative Therapies has a one year low of $1.03 and a one year high of $2.55.

BioRestorative Therapies (NASDAQ:BRTX) last issued its earnings results on Thursday, March 27th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.07. The business had revenue of $0.50 million for the quarter, compared to analysts’ expectations of $0.48 million. BioRestorative Therapies had a negative net margin of 2,697.08% and a negative return on equity of 98.49%. On average, equities research analysts predict that BioRestorative Therapies will post -1.43 earnings per share for the current fiscal year.

BioRestorative Therapies Company Profile

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.